

Sri Lanka Pharmaceuticals and Healthcare Report Q4 2016

https://marketpublishers.com/r/S8A61214369EN.html

Date: September 2016

Pages: 71

Price: US\$ 1,295.00 (Single User License)

ID: S8A61214369EN

Abstracts

Includes 3 FREE quarterly updates

BMI View: Sri Lanka's pharmaceutical and healthcare markets will continue to expand over the next 10 years driven by economic development. Despite an increased level of fiscal tightening in the coming quarters, healthcare system strengthening and facilities upgrade will remain a policy priority. We expect growing demand for healthcare and medical treatment of chronic diseases to create commercial opportunities for drugmakers and medical operators, although the government's pro-generic drugs stance and low spending per capita on medicine will continue to tarnish the market potential appeal to innovative drugmakers.

Headline Expenditure Projections

Pharmaceuticals: LKR82.88bn (USD610mn) in 2015 to LKR90.57bn (USD610mn) in 2016; +9.3 in local currency terms and +0.4 in US dollar terms. Forecast broadly in line with last quarter.

Healthcare: LKR273.32bn (USD2.01bn) in 2015 to LKR293.79bn (USD1.99bn) in 2016; +7.5 in local currency terms and -1.2 in US dollar terms. Forecast revised downwards from last quarter.



Contents

BMI Industry View

Table: Headline Pharmaceuticals & Healthcare Forecasts (Sri Lanka 2014-2020)

SWOT

Industry Forecast

Pharmaceutical Market Forecast

Table: Pharmaceutical Sales, Historical Data And Forecasts (Sri Lanka 2012-2020)

Healthcare Market Forecast

Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka

2012-2020)

Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sri

Lanka 2012-2020)

Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sri

Lanka 2012-2020)

Sri Lanka

Pharmaceutical Trade Forecast

Table: Pharmaceutical Trade Data And Forecasts (Sri Lanka 2014-2020)

Table: Pharmaceutical Trade Data And Forecasts local currency (Sri Lanka

2014-2020)

Industry Risk Reward Indices

Asia Pacific Risk/Reward Index - Q4 2016

Sri Lanka - Risk/Reward Index

Rewards

Risks

Regulatory Review

Intellectual Property Issues

Pricing And Reimbursement Regimes

Market Overview

Healthcare Sector

Clinical Trials

Epidemiology

Competitive Landscape

Research-Based Industry

Table: Multinational Market Activity

Pharmaceutical Distribution

Pharmaceutical Retail Sector

Company Profile

GlaxoSmithKline



Hemas Holdings

State Pharmaceuticals Corporation (SPC)

Demographic Forecast

Demographic Outlook

Table: Population Headline Indicators (Sri Lanka 1990-2025)

Table: Key Population Ratios (Sri Lanka 1990-2025)

Table: Urban/Rural Population & Life Expectancy (Sri Lanka 1990-2025)

Table: Population By Age Group (Sri Lanka 1990-2025)

Table: Population By Age Group % (Sri Lanka 1990-2025)

Glossary

Methodology

Pharmaceutical Expenditure Forecast Model

Healthcare Expenditure Forecast Model

Notes On Methodology

Risk/Reward Index Methodology

Index Overview

Table: Pharmaceutical Risk/Reward Index Indicators

Indicator Weightings



I would like to order

Product name: Sri Lanka Pharmaceuticals and Healthcare Report Q4 2016

Product link: https://marketpublishers.com/r/S8A61214369EN.html

Price: US\$ 1,295.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/S8A61214369EN.html